Xconomy -- Pervasis Therapeutics, a Cambridge, MA-based developer of cellular therapies, has had the green light from the FDA to start a pivotal clinical trial of its lead candidate for improving blood vessel access in hemodialysis patients for about a year. Yet the startup, whose board and advisors include major scientific stars such as MIT’s Bob Langer, hasn’t pulled the trigger on the trial needed for market approval.
